We are live on
!
Find out more
Temasek Holdings Portfolio holdings
AUM
$30.5B
1-Year Est. Return
13.98%
This Fund
S&P 500
This Quarter
Est. Return
+3.74%
1 Year Est. Return
+13.98%
3 Year Est. Return
+73.05%
5 Year Est. Return
+59.18%
10 Year Est. Return
+409.11%
AUM
$19B
AUM Growth
+$790M
(+4.3%)
Cap. Flow
+$345M
Cap. Flow
% of AUM
1.81%
Top 10 Holdings %
Top 10 Hldgs %
70.05%
Holding
71
New
1
Increased
12
Reduced
5
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lumen
LUMN
|
+$315M |
| 2 |
HDFC Bank
HDB
|
+$75M |
| 3 |
Global Payments
GPN
|
+$70.9M |
| 4 |
Mastercard
MA
|
+$35.4M |
| 5 |
PayPal
PYPL
|
+$35.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Virtu Financial
VIRT
|
+$111M |
| 2 |
MON
Monsanto Co
MON
|
+$50.1M |
| 3 |
Alibaba
BABA
|
+$19.6M |
| 4 |
AMRS
Amyris Inc.
AMRS
|
+$17.6M |
| 5 |
Amazon
AMZN
|
+$10.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 39.73% |
| 2 | Communication Services | 16.33% |
| 3 | Healthcare | 13.32% |
| 4 | Financials | 10.64% |
| 5 | Energy | 6.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ASLN
51
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
| $12.7M | 0.07% |
+35,562
| New | +$11M |
|
52
AC Immune
ACIU
$234M
| $12.5M | 0.07% |
1,337,500
| – | – |
|
53
Medtronic
MDT
$108B
| $9.19M | 0.05% |
107,300
+44,300
| +70% | +$3.7M |
|
54
Emerson Electric
EMR
$83.6B
| $8.57M | 0.05% |
123,908
| – | – |
|
55
Walt Disney
DIS
$168B
| $7.4M | 0.04% |
70,600
| – | – |
|
56
Rockwell Automation
ROK
$51.9B
| $7.38M | 0.04% |
44,409
| – | – |
|
57
Cognex
CGNX
$10.2B
| $6.21M | 0.03% |
139,192
| – | – |
|
|
AMRS
58
DELISTED
Amyris Inc.
AMRS
| $2.32M | 0.01% |
363,155
-2,939,430
| -89% | -$17.6M |
|
|
COUP
59
DELISTED
Coupa Software Incorporated
COUP
| $2.32M | 0.01% |
37,217
+13,380
| +56% | +$712K |
|
60
Okta
OKTA
$23.9B
| $355K | ﹤0.01% |
7,046
| – | – |
|
|
NETS
61
DELISTED
Netshoes (Cayman) Limited
NETS
| $302K | ﹤0.01% |
127,501
-1,943,626
| -94% | -$7.62M |
|
62
Bank of America
BAC
$436B
| – | – |
-234,724
| Closed | -$7.04M |
|
63
Goldman Sachs
GS
$309B
| – | – |
-6,132
| Closed | -$1.54M |
|
64
JPMorgan Chase
JPM
$947B
| – | – |
-78,220
| Closed | -$8.6M |
|
65
State Street SPDR S&P Regional Banking ETF
KRE
$4.47B
| – | – |
-152,603
| Closed | -$9.22M |
|
66
Morgan Stanley
MS
$337B
| – | – |
-32,273
| Closed | -$1.74M |
|
67
Senseonics Holdings Inc
SENS
$262M
| – | – |
-14,129
| Closed | -$848K |
|
68
Wells Fargo
WFC
$264B
| – | – |
-77,303
| Closed | -$4.05M |
|
|
RDUS
69
DELISTED
Radius Health, Inc.
RDUS
| – | – |
-19,344
| Closed | -$695K |
|
|
MON
70
DELISTED
Monsanto Co
MON
| – | – |
-429,184
| Closed | -$50.1M |
|
Similar funds
Temasek Holdings's Q2 2018 Portfolio in Review
As of Q2 2018, Temasek Holdings held 71 positions worth $19B, up 4.3% from $18.2B the previous quarter. Its ten largest holdings account for 70% of the portfolio.
Temasek Holdings's Q2 2018 filing shows 1 new, 12 increased, 5 reduced and 9 closed positions. Its largest new stake was ASLAN Pharmaceuticals Limited American Depositary Shares: 35,562 shares worth $12.7M. The largest sale was Virtu Financial, an estimated $111M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 40% of assets, down from 41% a quarter earlier, followed by Communication Services and Healthcare.
- Temasek Holdings's largest Q2 2018 buy was ASLAN Pharmaceuticals Limited American Depositary Shares: 35,562 shares worth $12.7M.
- Temasek Holdings added most to Lumen in Q2 2018, an estimated $315M increase.
- Temasek Holdings's biggest Q2 2018 reduction was Virtu Financial, cutting an estimated $111M.
- Temasek Holdings fully exited Monsanto Co in Q2 2018, selling an estimated $50.1M.
- Temasek Holdings's ten largest holdings make up 70% of its $19B portfolio in Q2 2018.
- Temasek Holdings opened 1 new position and closed 9 in Q2 2018.
- Temasek Holdings's portfolio value rose 4.3% quarter-over-quarter to $19B.
Based on Temasek Holdings's 13F filing for Q2 2018, filed 14 Aug 2018.